1. Home
  2. KPTI vs SNAL Comparison

KPTI vs SNAL Comparison

Compare KPTI & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.88

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Logo Snail Inc.

SNAL

Snail Inc.

HOLD

Current Price

$0.87

Market Cap

33.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPTI
SNAL
Founded
2008
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
94.6M
33.2M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
KPTI
SNAL
Price
$6.88
$0.87
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$22.17
N/A
AVG Volume (30 Days)
199.6K
29.3K
Earning Date
11-03-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,530,000.00
$82,330,445.00
Revenue This Year
$3.82
$13.87
Revenue Next Year
$3.18
$26.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.51
$0.64
52 Week High
$12.45
$3.42

Technical Indicators

Market Signals
Indicator
KPTI
SNAL
Relative Strength Index (RSI) 60.74 42.70
Support Level $5.99 $0.85
Resistance Level $7.48 $0.96
Average True Range (ATR) 0.53 0.06
MACD 0.06 0.00
Stochastic Oscillator 72.48 20.59

Price Performance

Historical Comparison
KPTI
SNAL

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.

Share on Social Networks: